

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | 1 | — | — | — | 2 |
| Melanoma | D008545 | — | — | 2 | 1 | — | — | — | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | 1 | 1 | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 1 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
| Drug common name | SOTIGALIMAB |
| INN | sotigalimab |
| Description | Sotigalimab is an antibody pharmaceutical. It is currently being investigated in clinical studies. |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | — |
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297888 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | JEA93WJ5DG (ChemIDplus, GSRS) |

